For research use only. Not for therapeutic Use.
8-OH-DPAT (8-Hydroxy-DPAT) hydrobromide is a potent and selective 5-HT1A agonist with a pIC50 of 8.19. 8-OH-DPAT hydrobromide has selectivity of almost 1000 fold for a subtype of the 5-HT1 binding site[1].
8-OH-DPAT (8-Hydroxy-DPAT) hydrobromide has no effect on 5-HT1B binding at concentrations lower than 100 nM[1].
8-OH-DPAT (8-Hydroxy-DPAT) hydrobromide (32, 56, 80, 100 mg/kg; intramuscularly; 15 min prior to the testing session) of the highest dose significantly interferes with sustained attention and reinforcer efficacy (progressive ratio; PR) performance in the 3,4-methylenedioxymethamphetamine (MDMA)-exposed but not control animals[1].
| Catalog Number | R048582 |
| CAS Number | 76135-31-4 |
| Synonyms | 7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol;hydrobromide |
| Molecular Formula | C16H26BrNO |
| Purity | ≥95% |
| InChI | InChI=1S/C16H25NO.BrH/c1-3-10-17(11-4-2)14-9-8-13-6-5-7-16(18)15(13)12-14;/h5-7,14,18H,3-4,8-12H2,1-2H3;1H |
| InChIKey | BATPBOZTBNNDLN-UHFFFAOYSA-N |
| SMILES | CCCN(CCC)C1CCC2=C(C1)C(=CC=C2)O.Br |
| Reference | [1]. D N Middlemiss, et al. 8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5-HT1 recognition site. Eur J Pharmacol. 1983 May 20;90(1):151-3. [2]. Michael A Taffe, et al. Cognitive performance of MDMA-treated rhesus monkeys: sensitivity to serotonergic challenge. Neuropsychopharmacology. 2002 Dec;27(6):993-1005. |
